Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 231

Similar articles for PubMed (Select 16950199)

1.

Effect of aspirin dose, preparation, and withdrawal on platelet response in normal volunteers.

Coleman JL, Alberts MJ.

Am J Cardiol. 2006 Sep 15;98(6):838-41. Epub 2006 Aug 2.

PMID:
16950199
2.

Recovery time of platelet function after aspirin withdrawal.

Lee J, Kim JK, Kim JH, Dunuu T, Park SH, Park SJ, Kang JY, Choi RK, Hyon MS.

Curr Ther Res Clin Exp. 2014 Mar 25;76:26-31. doi: 10.1016/j.curtheres.2014.02.002. eCollection 2014 Dec.

3.

In brief: enteric-coated aspirin as an antiplatelet drug.

[No authors listed]

Med Lett Drugs Ther. 2014 Apr 28;56(1441):36. No abstract available.

PMID:
24759295
4.

Response to letters regarding article, "Drug resistance and pseudoresistance: an unintended consequence of enteric coating aspirin".

Grosser T, Fries S, Lawson JA, Kapoor SC, Grant GR, Fitzgerald GA.

Circulation. 2013 Sep 17;128(12):e191. doi: 10.1161/CIRCULATIONAHA.113.004750. No abstract available.

5.

Integration of pharmacometabolomic and pharmacogenomic approaches reveals novel insights into antiplatelet therapy.

Lewis JP, Yerges-Armstrong LM, Ellero-Simatos S, Georgiades A, Kaddurah-Daouk R, Hankemeier T.

Clin Pharmacol Ther. 2013 Nov;94(5):570-3. doi: 10.1038/clpt.2013.153. Epub 2013 Jul 26. Review. No abstract available.

6.

Alternate-day, low-dose aspirin and cancer risk.

Rothwell PM.

Ann Intern Med. 2013 Jul 16;159(2):148-50. doi: 10.7326/0003-4819-159-2-201307160-00013. No abstract available.

PMID:
23856684
7.

Drug resistance and pseudoresistance: an unintended consequence of enteric coating aspirin.

Grosser T, Fries S, Lawson JA, Kapoor SC, Grant GR, FitzGerald GA.

Circulation. 2013 Jan 22;127(3):377-85. doi: 10.1161/CIRCULATIONAHA.112.117283. Epub 2012 Dec 4.

8.

Irbesartan does not influence the antiplatelet effect of aspirin in spontaneously hypertensive rats.

Hu GL, Leng WX, Wang X, Lu XC, Liu AJ, Cui H, Cao J, Fan L.

CNS Neurosci Ther. 2012 Aug;18(8):709-10. doi: 10.1111/j.1755-5949.2012.00350.x. Epub 2012 Jun 28. No abstract available.

PMID:
22742580
9.

Prediction of time-dependent interaction of aspirin with ibuprofen using a pharmacokinetic/pharmacodynamic model.

Awa K, Satoh H, Hori S, Sawada Y.

J Clin Pharm Ther. 2012 Aug;37(4):469-74. doi: 10.1111/j.1365-2710.2011.01313.x. Epub 2011 Nov 28.

PMID:
22122406
10.

Antiplatelet therapy: Discontinuation of low-dose aspirin reverses its prophylactic effect.

Lim GB.

Nat Rev Cardiol. 2011 Aug 9;8(10):542. doi: 10.1038/nrcardio.2011.123. No abstract available.

PMID:
21826069
11.

Laboratory signs of aspirin response in haemodialysis patients.

Kilickesmez KO, Kocas C, Okcun B, Abaci O, Kaya A, Arat A, Gorcin B, Gurmen T.

Scand J Clin Lab Invest. 2011 Sep;71(5):426-31. doi: 10.3109/00365513.2011.581388. Epub 2011 May 9.

PMID:
21554056
12.
13.

Effects of different doses, enteric-coated preparation of aspirin, and sex on urinary 11-dehydrothromboxane B2 in healthy volunteers.

Dharmasaroja PA, Sae-Lim S.

Blood Coagul Fibrinolysis. 2010 Oct;21(7):649-52. doi: 10.1097/MBC.0b013e32833cea2c.

PMID:
20689403
14.

The role of weight and enteric coating on aspirin response in cardiovascular patients.

Peace A, McCall M, Tedesco T, Kenny D, Conroy RM, Foley D, Cox D.

J Thromb Haemost. 2010 Oct;8(10):2323-5. doi: 10.1111/j.1538-7836.2010.03997.x. No abstract available.

PMID:
20653839
15.

Randomized, double-blind, pilot study of geranylgeranylacetone versus placebo in patients taking low-dose enteric-coated aspirin. Low-dose aspirin-induced small bowel damage.

Shiotani A, Haruma K, Nishi R, Fujita M, Kamada T, Honda K, Kusunoki H, Hata J, Graham DY.

Scand J Gastroenterol. 2010 Mar;45(3):292-8. doi: 10.3109/00365520903453182.

PMID:
19968611
16.

Dual antiplatelet drug resistance in patients with acute coronary syndrome.

Guha S, Sardar P, Guha P, Roy S, Mookerjee S, Chakrabarti P, Deb PK, Chaudhuri U, Deb S, Karmakar R, Dasgupta AK, Lahiri P.

Indian Heart J. 2009 Jan-Feb;61(1):68-73.

PMID:
19729693
17.

Platelet inhibitory effects of OTC doses of naproxen sodium compared with prescription dose naproxen sodium and low-dose aspirin.

Schiff M, Hochberg MC, Oldenhof J, Brune K.

Curr Med Res Opin. 2009 Oct;25(10):2471-7. doi: 10.1185/03007990903185706.

PMID:
19678751
18.

Cross validation of the Multiple Electrode Aggregometry. A prospective trial in healthy volunteers.

Siller-Matula JM, Gouya G, Wolzt M, Jilma B.

Thromb Haemost. 2009 Aug;102(2):397-403. doi: 10.1160/TH08-10-0669.

PMID:
19652892
19.

Do proton pump inhibitors attenuate the effect of aspirin on platelet aggregation? A randomized crossover study.

Adamopoulos AB, Sakizlis GN, Nasothimiou EG, Anastasopoulou I, Anastasakou E, Kotsi P, Karafoulidou A, Stergiou GS.

J Cardiovasc Pharmacol. 2009 Aug;54(2):163-8. doi: 10.1097/FJC.0b013e3181af6d9c.

PMID:
19568178
20.

[Difficulties in evaluating the efficacy of antiplatelet therapy in clinical practice].

Buriachkovskaia LI, Uchitel' IA, Sumarokov AV, Popov EG.

Ter Arkh. 2009;81(5):41-7. Russian.

PMID:
19537585
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk